While the market fixates on AI spending sprees and stretched tech valuations, an old-economy Dividend King has been quietly outperforming — and even leaving Alphabet in the dust.
Shares of Altria Group (MO), America’s largest tobacco company, have climbed 24% year to date, handily beating Google parent Alphabet’s 13% gain. For income-focused investors, the real comfort lies in the payout: Altria has raised its dividend 60 times over the past 56 years, cementing its place in the S&P 500’s tiny club of Dividend Kings. The stock now offers a forward yield of about 5.8%, well above the 4.6% on 10-year Treasurys, and the dividend consumed just 81% of free cash flow over the last 12 months — leaving a comfortable safety cushion.
Altria’s staying power seems to defy the times. Its flagship Marlboro brand still drives more than 90% of revenue, even though adult smoking rates in the U.S. have been falling for six decades. The company has simply pushed prices higher, kept a tight lid on costs, and bought back stock so aggressively that earnings per share kept climbing despite shrinking cigarette volumes. Over the past five years, Altria retired roughly 9% of its shares; the stock rose 56% in that stretch, and total return with dividends reinvested hit 129%.
More important, Altria is trying to reshape itself from a pure-play cigarette maker into what it calls a “reduced harm” tobacco platform. After acquiring NJOY, the leading U.S. e-cigarette brand, in 2023 and rapidly expanding its On! nicotine pouch business, the company has established a genuine foothold in smoke-free products. Management’s stated target: at least $5 billion in smoke-free revenue by 2028, or about 24% of projected total sales, to offset declining cigarette shipments.
In the first quarter, revenue rose 3.2% to $5.43 billion, and adjusted diluted EPS more than doubled to $1.30. The company reaffirmed its full-year 2026 adjusted EPS guidance of $5.56 to $5.72, implying 2.5% to 5.5% growth from a 2025 base of $5.42. Analysts now expect the smoke-free transformation and other catalysts to drive a 13% compound annual growth rate in EPS from 2025 through 2028. At less than 13 times forward earnings, the valuation still offers a clear margin of safety.
Altria also enjoys a near-total insulation from the ongoing tariff skirmishes and trade wars, since it produces and sells virtually all its products within the United States. And a potential FDA crackdown on illegal or niche alternative nicotine products could steer more market share toward its compliant portfolio.
Make no mistake: this is the quintessential sin stock. The CDC attributes roughly 480,000 American deaths a year to smoking-related illness, and the global toll exceeds 8 million. That moral weight keeps large swaths of ESG-driven capital and ethically minded individual investors at arm’s length. But it is precisely this persistent exclusion from the mainstream that keeps Altria’s valuation depressed — and hands contrarian investors meaningful dividend income along with capital appreciation.
While tech giants burn cash and take on debt to finance AI infrastructure, and while the macro picture stays clouded by sticky inflation and geopolitical uncertainty, Altria offers an almost boring kind of dependability. Addiction-driven demand produces steady cash flows, steady cash flows support a steadily rising dividend, and that dividend acts as a natural ballast against volatility. The stock that has quietly climbed 24% this year, with 60 dividend hikes over 56 years, delivers a straightforward reminder: the crown of a Dividend King is earned not by sector glamour, but by long-term discipline and an unwavering commitment to shareholder returns.
